Joint Formulary & PAD

Depemokimab - Rhinosinusitis with nasal polyps

You are here : Home > Formulary Search > Depemokimab - Rhinosinusitis with nasal polyps

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Pre-filled pen
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NFD2
SPC
Restrictions / Comments :
Important

This drug has not been assessed for formulary status.

NICE is unable to make a recommendation because the company has not provided an evidence submission. As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug it is recommended that clinicians contact their Medicines      Optimisation team to discuss possible alternatives/options.

If a specialist team would like the APC to consider adding this treatment to the Joint Formulary. They should contact the team at syheartlandsicb.apc@nhs.net and the team will provide support for the submission.

Documentation

NICE Technology Appraisal
NICE TA1123 -Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (TERMINATED APPRAISAL)

PAD Profile

ChemicalSubstance :
Depemokimab
Indication :
Rhinosinusitis with nasal polyps
Group Name :
Keywords :
Nasal Polyps, CRSwNP, Sinus
Brand Names Include :
EXDENSUR
Important Information :
Latest Additions Date From :
04 Feb 2026
Latest Additions Date To :
04 Mar 2026
Guidelines :
Supporting Documents :
1

Committee Recommendations (0)

  • No records returned.

Other Indications

Below are listed other indications that Depemokimab is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Rhinosinusitis with nasal polyps .

  • No records returned.